Bio-Rad Laboratories introduced a range of type 1 antibodies that inhibit the binding of evolocumab (Repatha®) to its target, human proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that has been shown to play a key role in the regulation of cholesterol levels. The antibodies can be used to develop PK bridging ELISAs to measure free drug or as a surrogate positive control or reference standard in an ADA assay. According to the company, the anti-evolocumab antibodies are approved for in vitro research purposes and for commercial in vitro testing services to support preclinical and clinical drug development.